{"id":"https://genegraph.clinicalgenome.org/r/44f48f14-6622-4edb-a54e-0bcff066d6f1v1.0","type":"EvidenceStrengthAssertion","dc:description":"*RAC1* was first reported in relation to autosomal dominant syndromic intellectual disability (ID) in 2016 in a large cohort of ID patient-parent trios (Lelieveld et al., PMID: 27479843), and was subsequently described in detail in 7 individuals with syndromic ID in 2017 (Reijnders et al., PMID: 28886345). *RAC1* encodes a RHO GTPase that plays a role in the development and function of the nervous system, including regulation of neuronal morphology and migration. Affected individuals present with developmental delay, mild-to-severe ID, dysmorphic facial features, micro/macrocephaly, and abnormal brain MRI findings; more variable features include hypotonia, epilepsy, autism, congenital heart defects, and skin abnormalities (PMIDs: 28886345, 34725860, 35139179, 37059841). \n\nFourteen unique *RAC1* missense variants reported in 14 probands in 5 publications (PMIDs: 28886345, 34725860, 35139179, 37059841, 37328543) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 points) has been reached. Most variants are *de novo*. The majority of variants have been found to cluster at residues Q61–R68 in the switch II region of *RAC1*, with 4 unrelated patients harboring the same *de novo* p.Y64D variant. Variants in the switch II region are reported to be constitutively active, whereas most variants outside the switch II region, including variants in the switch I region, are reported to exert a dominant negative effect; further functional characterization is needed to determine the effect of variants within each region (PMIDs: 28886345, 34725860, 35139179, 37059841). \n\nThis gene-disease relationship is also supported by experimental evidence, including *in vitro* functional assays, biochemical function, protein interaction, and mouse, drosophila and zebrafish models (PMIDs: 28886345, 32109419, 34557485, 35139179, 37059841).\n\nIn summary, there is definitive evidence to support the relationship between *RAC1* and autosomal dominant syndromic ID. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on September 20, 2023 (SOP Version 10).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/44f48f14-6622-4edb-a54e-0bcff066d6f1","GCISnapshot":"https://genegraph.clinicalgenome.org/r/da151217-aee4-4a00-9ae1-d8b610eb216e","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/da151217-aee4-4a00-9ae1-d8b610eb216e_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2023-09-20T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/da151217-aee4-4a00-9ae1-d8b610eb216e_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2024-06-04T23:47:47.330Z","role":"Publisher"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/da151217-aee4-4a00-9ae1-d8b610eb216e_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/da151217-aee4-4a00-9ae1-d8b610eb216e_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/46a06a9a-0c82-4659-805b-fb265f1b3199","type":"EvidenceLine","dc:description":"Downgraded due to non-mammalian model organism","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/35b80a62-1d7e-49c4-a76a-6bcf074fa823","type":"Finding","dc:description":"Drosophila Rac1-Y64D model displayed abnormal axonal growth and morphology, abnormal axonal organization, and abnormal dendritic branching of sensory neurons ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35139179","rdfs:label":"Drosophila Rac1-Y64D transgenic model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/f2835441-b390-4f44-92c0-b00bf357c37c","type":"EvidenceLine","dc:description":"Downgraded due to lack of behavioral or additional phenotype information","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11a38bfe-dd64-46fe-877c-814709fa856d","type":"Finding","dc:description":"RAC1 constitutively active mouse model leads to increased proliferation rate, altered cell density, and migration pattern of neural crest cells and disruption of ventral midbrain dopaminergic neuron precursors ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34557485","rdfs:label":"Mouse Rac1 constitutively active model (Rac1-G12V)","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/2de0f872-dfaa-4aca-b837-87e7a3edafd1","type":"EvidenceLine","dc:description":"Downgraded due to non-mammalian model organism","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a2cccb9f-76a5-496c-a5b4-45bdbd81b5cd","type":"Finding","dc:description":"Zebrafish constitutively active and dominant negative models induced head size changes, neuronal proliferation changes, and cerebellar defects; micro/macrocephaly have been reported in human patients ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28886345","rdfs:label":"Zebrafish models (DN, CA and KO models)","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/da151217-aee4-4a00-9ae1-d8b610eb216e_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7fd7b038-0f12-491f-b586-643e764dbcc0","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/acc76c8f-28c9-4e00-aea0-431e8b75e187","type":"FunctionalAlteration","dc:description":"Activating RAC1 switch II variants (Y64D, Y64C and R68G) in fibroblasts promotes activation of downstream signalling targets (WRC and PAK) involved in regulating lamellipodia assembly in fibroblasts and axonal growth as well as initiation of collateral branches on axons and dendrites in neurons (WRC), and cell survival, proliferation and metabolism (PAK)","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35139179","rdfs:label":"RAC1 variants promote activation of downstream targets"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/da151217-aee4-4a00-9ae1-d8b610eb216e_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/817bf453-ffc7-4015-8c45-0e995f6595ef","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aefbb896-9eff-4cd9-9f87-7591d57e74f7","type":"Finding","dc:description":"RAC1 is a RHO GTPase involved in cellular growth and cell-cycle regulation; other RAC genes and similar Ras-related GTP-binding genes are also associated with ID or ID syndromes: RAC3 (Neurodevelopmental disorder with structural brain anomalies and dysmorphic facies) and CDC42 (Takenouchi-Kosaki syndrome)\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37059841","rdfs:label":"RHO GTPase/Ras-related GTP-binding gene protein function ","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0de6e366-6a6c-4c67-bfab-8f75289800d3","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a553bdcd-2324-4342-8e19-bf144a9a9712","type":"Finding","dc:description":"TRIO acts as a key regulator of neuronal migration, axonal outgrowth, axon guidance, and synaptogenesis by activating the GTPase RAC1 and modulating actin cytoskeleton remodeling; TRIO variants are associated with ID. Patient variants in specific TRIO domains (spectrin and GEFD1) either cause hyper- or hypo-activation of RAC1, respectively, and result in opposite effects on RAC1 activation levels and macrocephaly (spectrin variants) or microcephaly (GEFD1 variants) in patients","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32109419","rdfs:label":"RAC1-TRIO Interaction","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4.5},{"id":"https://genegraph.clinicalgenome.org/r/da151217-aee4-4a00-9ae1-d8b610eb216e_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/180af8d8-2c56-4085-9a70-4f071b6115c2","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/180af8d8-2c56-4085-9a70-4f071b6115c2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RAC1 Y64D variant exhibits altered fibroblast spreading morphology consistent with constitutively active phenotype","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/180af8d8-2c56-4085-9a70-4f071b6115c2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35139179","allele":{"id":"https://genegraph.clinicalgenome.org/r/823a05d6-a54f-44d7-b714-418ba2af6346","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006908.5(RAC1):c.190T>G (p.Tyr64Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366761303"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/c222df80-56a2-4ce4-916b-5d48a578345c","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c222df80-56a2-4ce4-916b-5d48a578345c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RAC1 Y64C variant exhibits altered fibroblast spreading morphology consistent with constitutively active phenotype","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/c222df80-56a2-4ce4-916b-5d48a578345c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35139179","allele":{"id":"https://genegraph.clinicalgenome.org/r/f1c38dbe-5868-4a1f-8cc6-91dd13e395f5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006908.5(RAC1):c.191A>G (p.Tyr64Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366761313"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/bedf35f4-c6f3-4dc1-ac9c-a2902c593400","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bedf35f4-c6f3-4dc1-ac9c-a2902c593400_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34725860","allele":{"id":"https://genegraph.clinicalgenome.org/r/70ec9289-4a39-4cc3-937e-e20104623496","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006908.5(RAC1):c.94T>C (p.Tyr32His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366760129"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/46ae4c66-af12-4b99-a9d4-36e49bebf447","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/46ae4c66-af12-4b99-a9d4-36e49bebf447_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RAC1 Q61E variant exhibits altered fibroblast spreading morphology consistent with constitutively active phenotype","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/46ae4c66-af12-4b99-a9d4-36e49bebf447_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35139179","allele":{"id":"https://genegraph.clinicalgenome.org/r/34eec2c0-0d34-46f9-b53e-5a69ac9b7c49","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006908.5(RAC1):c.181C>G (p.Gln61Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366761207"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/5f8e1b58-59a6-4c18-bd3f-b2eefda6c5f9","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5f8e1b58-59a6-4c18-bd3f-b2eefda6c5f9_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RAC1 A159T variant demonstrates constitutively active phenotype based on cell morphology and GTP-bound pull down assays","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/5f8e1b58-59a6-4c18-bd3f-b2eefda6c5f9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37059841","allele":{"id":"https://genegraph.clinicalgenome.org/r/c414a21a-6f46-4a8b-a212-f75ca93addcc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006908.5(RAC1):c.475G>A (p.Ala159Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366766833"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/183e6754-be20-4d6d-89ff-eefa0577175a","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/183e6754-be20-4d6d-89ff-eefa0577175a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Variation at RAC1 R68 residue results in altered fibroblast spreading morphology consistent with constitutively active phenotype","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/183e6754-be20-4d6d-89ff-eefa0577175a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35139179","allele":{"id":"https://genegraph.clinicalgenome.org/r/ba7944d4-b73f-44d7-ab56-c5cb423bfb75","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006908.5(RAC1):c.202C>A (p.Arg68Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366761456"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c3374ca9-5159-4663-9618-9d06ab01dbae","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c3374ca9-5159-4663-9618-9d06ab01dbae_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RAC1 N39S variant exhibits altered fibroblast spreading consistent with known dominant negative variants.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/c3374ca9-5159-4663-9618-9d06ab01dbae_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28886345","allele":{"id":"https://genegraph.clinicalgenome.org/r/8be4fbb6-3f76-4aad-813f-caa51e885768","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006908.5(RAC1):c.116A>G (p.Asn39Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366760717"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/6f4bb009-b65f-49c2-8265-651980000879","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6f4bb009-b65f-49c2-8265-651980000879_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Pull-down assays demonstrated that RAC1-p.Tyr40His interacted minimally with PAK1 (a well-characterized downstream effector of RAC1) and did not enable PAK1 activation.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/6f4bb009-b65f-49c2-8265-651980000879_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37328543","allele":{"id":"https://genegraph.clinicalgenome.org/r/1911a0ec-77dc-44fb-a53e-c4d97eae5a53","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006908.5(RAC1):c.118T>C (p.Tyr40His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366760726"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/79a20921-3aed-4a7e-9ba0-990191c49ff5","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/79a20921-3aed-4a7e-9ba0-990191c49ff5_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RAC1 Y64D variant exhibits altered fibroblast spreading morphology consistent with constitutively active phenotype","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/79a20921-3aed-4a7e-9ba0-990191c49ff5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35139179","allele":{"id":"https://genegraph.clinicalgenome.org/r/823a05d6-a54f-44d7-b714-418ba2af6346"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ffeaf8aa-014f-47c4-8faa-bc60d23b6253","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ffeaf8aa-014f-47c4-8faa-bc60d23b6253_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RAC1 Y64D variant exhibits altered fibroblast spreading consistent with known constitutively active variants.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/ffeaf8aa-014f-47c4-8faa-bc60d23b6253_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28886345","allele":{"id":"https://genegraph.clinicalgenome.org/r/823a05d6-a54f-44d7-b714-418ba2af6346"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/1719d813-572d-43d9-96de-a2f86e043cde","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1719d813-572d-43d9-96de-a2f86e043cde_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RAC1 R68G variant exhibits altered fibroblast spreading morphology consistent with constitutively active phenotype","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/1719d813-572d-43d9-96de-a2f86e043cde_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35139179","allele":{"id":"https://genegraph.clinicalgenome.org/r/cfd4f648-2c7a-4eaf-aa8a-ae56a5e6c4d1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006908.5(RAC1):c.202C>G (p.Arg68Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366761467"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/24a6bce6-a9e8-42f7-be49-87daf8b2e2c3","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/24a6bce6-a9e8-42f7-be49-87daf8b2e2c3_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RAC1 Y64D variant exhibits altered fibroblast spreading morphology consistent with constitutively active phenotype","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/24a6bce6-a9e8-42f7-be49-87daf8b2e2c3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35139179","allele":{"id":"https://genegraph.clinicalgenome.org/r/823a05d6-a54f-44d7-b714-418ba2af6346"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/9daf2e0f-eead-450c-a85a-eda1d38c871a","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9daf2e0f-eead-450c-a85a-eda1d38c871a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RAC1 E62K variant demonstrates activating effect based on cell morphology and GTP-bound pull down assays, and increased protein degradation by proteosome","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/9daf2e0f-eead-450c-a85a-eda1d38c871a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37059841","allele":{"id":"https://genegraph.clinicalgenome.org/r/ab2924f5-4c81-445d-8f7d-8ebf596d2f66","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006908.5(RAC1):c.184G>A (p.Glu62Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366761235"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/bf177c89-4d0f-43ef-a37c-d8a88fd78188","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bf177c89-4d0f-43ef-a37c-d8a88fd78188_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RAC1 C18Y variant exhibits altered fibroblast spreading consistent with known dominant negative variants.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/bf177c89-4d0f-43ef-a37c-d8a88fd78188_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28886345","allele":{"id":"https://genegraph.clinicalgenome.org/r/25718929-44a6-4f0f-bb46-7ae3cf4d00d0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006908.5(RAC1):c.53G>A (p.Cys18Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366759929"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":8349,"specifiedBy":"GeneValidityCriteria10","strengthScore":16.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/GImOQ0ejJHw","type":"GeneValidityProposition","disease":"obo:MONDO_0000508","gene":"hgnc:9801","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_da151217-aee4-4a00-9ae1-d8b610eb216e-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}